List of Excipients in Branded Drug NITISINONE

Generic Drugs Containing NITISINONE

Company	Ingredient	NDC	Excipient
Endo USA Inc	nitisinone	0254-3020	AMMONIA
Endo USA Inc	nitisinone	0254-3020	ANHYDROUS CITRIC ACID
Endo USA Inc	nitisinone	0254-3020	FERROSOFERRIC OXIDE
Endo USA Inc	nitisinone	0254-3020	GELATIN
Endo USA Inc	nitisinone	0254-3020	HYPROMELLOSE 2910
Endo USA Inc	nitisinone	0254-3020	MANNITOL

What are the Most Frequently-Used Excipients in NITISINONE?

# Of NDCs	Excipient
6	AMMONIA
4	ANHYDROUS CITRIC ACID
1	ANHYDROUS LACTOSE
1	FD&C BLUE NO. 2--ALUMINUM LAKE
4	FERROSOFERRIC OXIDE
6	GELATIN

Nitisinone Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Nitisinone is a small-molecule orphan drug used with dietary restriction to treat hereditary tyrosinemia type 1 (HT-1). The commercial opportunity is concentrated in pediatric formulation performance, dose flexibility, global access, supply reliability, and differentiation from existing capsule, tablet, and oral-suspension products.

The main marketed products are Orfadin, supplied by Swedish Orphan Biovitrum, and Nityr, supplied by Cycle Pharmaceuticals. Orfadin is available as capsules and an oral suspension. Nityr is available as immediate-release tablets in 2 mg, 5 mg, and 10 mg strengths.[1-4]

What is the current nitisinone product and regulatory landscape?

Nitisinone inhibits 4-hydroxyphenylpyruvate dioxygenase, reducing the production of toxic downstream metabolites in HT-1. Treatment requires concurrent restriction of tyrosine and phenylalanine intake, with regular monitoring of plasma tyrosine and liver-related biomarkers.[1,2]

Product	Manufacturer or sponsor	Dosage forms	Strengths	Primary FDA indication
Orfadin	Swedish Orphan Biovitrum	Capsules; oral suspension	Capsules: 2, 5, 10 mg; suspension: 4 mg/mL	HT-1 with dietary restriction
Nityr	Cycle Pharmaceuticals	Immediate-release tablets	2, 5, 10 mg	HT-1 with dietary restriction

Orfadin capsules received FDA approval in 2002. Orfadin oral suspension was later approved to address administration needs, particularly in younger children. Nityr tablets received FDA approval in 2017.[1-4]

Nitisinone is an orphan-designated product class. The original orphan exclusivity period for the initial indication has expired. Current commercial protection therefore depends more heavily on formulation rights, regulatory status, manufacturing controls, brand recognition, supply reliability, and any unexpired patents listed in the FDA Orange Book or national patent registers.

What excipients are used in marketed nitisinone products?

The marketed products use conventional solid-dose excipient systems rather than highly differentiated delivery technologies.

Orfadin capsules

Orfadin capsules use a conventional hard-gelatin capsule formulation. Label-listed inactive ingredients include lactose monohydrate, pregelatinized starch, talc, and magnesium stearate. Capsule-shell colorants vary by strength and may include titanium dioxide and iron oxides.[1]

This formulation has several commercial implications:

• Lactose may limit use in patients or markets seeking lactose-free products.
• Pregelatinized starch supports powder flow and capsule filling.
• Talc and magnesium stearate assist manufacturing performance.
• Capsule dosing is less suitable for infants and children unable to swallow solid dosage forms.
• Color differentiation supports dose identification but increases the number of controlled components.

Orfadin oral suspension

Orfadin oral suspension uses a granule-based system intended for reconstitution and measurement as a liquid. The suspension format addresses pediatric administration, but it introduces additional quality requirements:

• Reconstitution uniformity
• Redispersibility after storage
• Dose accuracy across the labeled volume
• Microbial control
• Container-closure compatibility
• Stability after reconstitution
• Control of sedimentation and aggregation

A suspension creates a larger excipient and manufacturing burden than a capsule or tablet. Its commercial value comes from usability rather than low production cost.

Nityr tablets

Nityr tablets use standard direct-compression or granulation excipients, including microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate, with a film-coat system for product identification and handling.[2]

The tablet platform offers:

• Better portability than a liquid
• Lower packaging complexity
• No reconstitution step
• Easier distribution through pharmacies
• Potentially lower manufacturing and logistics costs than a liquid suspension

The main limitation is pediatric administration. Tablets may not be appropriate for very young children or patients who cannot swallow.

What excipient strategy best fits nitisinone?

The strongest strategy is a segmented platform rather than a single universal formulation.

Target segment	Preferred dosage form	Excipient priority	Commercial objective
Infants and young children	Ready-to-use liquid or dispersible solid	Taste masking, suspension stability, low microbial risk	Improve administration and adherence
Children able to swallow	Low-strength tablet or mini-tablet	Content uniformity, rapid disintegration	Reduce dosing burden
Adolescents and adults	Tablet or capsule	Low cost, stability, portability	Compete on access and supply
Global low-resource markets	Stable tablet or dry suspension	Heat and humidity resistance	Simplify distribution
Patients requiring flexible doses	Scored tablet, dispersible tablet, or calibrated liquid	Accurate fractional dosing	Expand usability

Nitisinone products require very low strengths, particularly at treatment initiation or in small children. The primary technical challenge is not the amount of excipient. It is uniform distribution of a low-dose active pharmaceutical ingredient through the blend and finished dosage unit.

A viable formulation program should prioritize:

1. Assay and content-uniformity robustness at 2 mg and below.
2. Rapid and reproducible disintegration.
3. Dose flexibility without unvalidated tablet splitting.
4. Taste acceptability for pediatric administration.
5. Low hygroscopicity and strong stability under climatic stress.
6. Minimal excipient count where supply security matters.
7. Compatibility with automated pediatric dispensing.

What pediatric formulation opportunities exist for nitisinone?

The highest-value opportunity is a child-friendly formulation that improves dosing accuracy without creating the handling problems of a traditional suspension.

Ready-to-use oral liquid

A ready-to-use liquid could remove the reconstitution step associated with granule-based suspension products. Key development issues would include:

• Nitisinone solubility or controlled suspension design
• Chemical stability in an aqueous environment
• Preservative selection
• Taste masking
• Accurate dosing at low volumes
• Compatibility with oral syringes
• Light protection
• Container-closure extractables and leachables

A ready-to-use product would have stronger convenience value than a powder-for-reconstitution product but would carry higher shipping weight and greater microbial-control requirements.

Dispersible tablet

A dispersible tablet could occupy the space between capsules and liquids. It could be dispersed in a small volume of water before administration, reducing the need for a bottle, measuring device, and preservative system.

The formulation would need rapid dispersion, low residue, acceptable mouthfeel, and dose integrity after dispersion. A dispersible tablet also creates potential intellectual-property positions around disintegration time, particle-size distribution, taste masking, and administration volume.

Mini-tablet or multiparticulate formulation

Mini-tablets or coated multiparticulates could improve pediatric dosing while avoiding a conventional liquid. Multiparticulates may be administered with a small amount of soft food, subject to regulatory and labeling validation.

This platform could support multiple dose strengths through sachets or capsules containing metered units. Manufacturing complexity would be higher than for a standard tablet, but dose flexibility and swallowing performance could justify premium pricing.

What formulation patents could protect a new nitisinone product?

Formulation patents could protect the dosage form rather than nitisinone itself. The strongest claim categories would likely involve measurable technical characteristics.

Potential patent claim areas

• A stable aqueous nitisinone suspension
• A specific particle-size distribution
• A defined polymorphic or crystalline form
• A dispersible tablet with a specified disintegration profile
• Taste-masked nitisinone particles
• A low-dose tablet with improved content uniformity
• A formulation with improved dissolution or bioavailability
• A preservative system with defined stability
• A container and dosing system that maintains dose accuracy
• A manufacturing process that reduces assay variability

A broad claim covering "nitisinone plus conventional excipients" would face substantial validity and obviousness risk. A stronger patent position would link the excipient system to a demonstrated technical result, such as improved suspension stability, reduced degradation, improved palatability, or better dose uniformity.

For a new entrant, the commercial value of formulation patents would be highest when combined with regulatory exclusivity, pediatric data, device protection, and manufacturing know-how.

When does nitisinone lose exclusivity?

The original orphan exclusivity associated with the initial FDA approval is no longer the principal barrier to competition. Nitisinone already has competing branded products, including Orfadin and Nityr.[1-4]

Exclusivity or barrier	Commercial status
Active ingredient exclusivity	Expired as a practical market barrier
Original orphan exclusivity	Expired for the original approval period
Product-specific formulation rights	May remain relevant depending on patent scope and term
Method-of-use rights	Must be assessed by indication and claim language
Pediatric exclusivity	Product- and study-specific; not assumed to apply broadly
Manufacturing know-how	Potentially important but generally not publicly visible
Regulatory exclusivity for a new formulation	Could arise if the FDA grants a qualifying period for a new product

A patent-expiration date should not be inferred from the approval date. Product-specific patent status must be checked against current FDA Orange Book listings, patent-term adjustments, terminal disclaimers, litigation records, and post-grant proceedings.

What is the Orange Book and Paragraph IV risk for nitisinone?

Nitisinone presents a conventional small-molecule generic-entry pathway. A prospective generic sponsor could use an abbreviated new drug application if it can demonstrate pharmaceutical equivalence, bioequivalence, stability, manufacturing control, and compliance with applicable reference-product requirements.

Potential Paragraph IV targets could include:

• Capsule formulations
• Tablet formulations
• Oral-suspension formulations
• Listed formulation patents
• Method-of-use patents
• Device or container claims, where legally relevant

The commercial risk differs by dosage form. A generic tablet may be easier to develop than a pediatric suspension because the suspension requires more extensive control of particle size, redispersibility, dose uniformity, and microbial quality.

A Paragraph IV challenge would not automatically produce immediate market entry. Entry would depend on patent litigation, the 30-month stay, court findings, settlement terms, and any applicable exclusivity. Publicly available product labels do not establish a complete current patent-expiration analysis.

Which companies are challenging or competing with nitisinone products?

The competitive field is limited but meaningful.

Swedish Orphan Biovitrum

Sobi markets Orfadin, which has the broadest dosage-form coverage among the established products, including capsules and oral suspension. Its principal advantages are historical market presence, physician familiarity, and pediatric liquid availability.

Cycle Pharmaceuticals

Cycle markets Nityr tablets. Its product provides a tablet-based alternative with 2 mg, 5 mg, and 10 mg strengths. The main competitive position is a differentiated solid oral product rather than a new active ingredient.

Generic manufacturers

Generic companies could compete through tablets or capsules, but pediatric liquid development may be more difficult. A generic entrant would need to evaluate whether the reference suspension can be adequately replicated through an ANDA or whether a different regulatory pathway is required.

Biosimilar risk

There is no biosimilar pathway for nitisinone. Nitisinone is a chemically synthesized small molecule, not a biologic. Competition would arise through generic, hybrid, or independently approved formulation pathways rather than biosimilar development.

What licensing deals affect nitisinone commercial opportunities?

Public product ownership and commercialization arrangements are more visible than formulation-specific licensing deals. Orfadin is associated with Sobi, while Nityr is associated with Cycle Pharmaceuticals.[1,2]

A new entrant should treat formulation licensing as a separate question from brand commercialization. The highest-value licensing targets could include:

• Pediatric liquid technology
• Taste-masking technology
• Low-dose content-uniformity technology
• Oral syringe or dosing-device platforms
• Stabilized suspension systems
• Contract manufacturing capacity for orphan products
• Regional distribution rights

Because the patient population is small, a formulation license must be assessed against minimum purchase commitments, global registration costs, pharmacovigilance obligations, and the need to maintain multiple strengths.

What manufacturing and IP barriers affect nitisinone?

Manufacturing barriers are moderate for conventional tablets and higher for liquids and multiparticulates.

Tablet and capsule barriers

The principal risks are low-dose content uniformity, blend segregation, API particle-size control, dissolution reproducibility, and stability. A robust process may require premixing, geometric dilution, controlled lubrication, and in-process sampling.

Suspension barriers

Suspension products require control of sedimentation, redispersion, viscosity, preservative effectiveness, microbial limits, and dosing accuracy. Packaging must protect the product from light and prevent inaccurate dosing after repeated use.

Global supply barriers

Orphan products can be exposed to disproportionate supply-chain risk because demand is low and the number of qualified suppliers is limited. Commercial advantages may come from:

• Dual sourcing of critical excipients
• Regional packaging
• Reduced dependence on specialty colorants
• Climatic-zone stability data
• Longer shelf life
• Smaller minimum production campaigns

Excipient selection should favor pharmacopeial grades with more than one qualified supplier. A proprietary excipient can support differentiation but may weaken supply resilience and complicate global registration.

How does nitisinone compare with competing rare-disease products?

Nitisinone has a smaller formulation opportunity than many chronic rare-disease drugs because the active ingredient is already available in several dosage forms. The opportunity is strongest where the existing products impose administration or access costs.

Dimension	Nitisinone market	Commercial implication
Patient population	Small, specialized	Premium pricing may be possible, but volume is limited
Treatment duration	Chronic	Adherence and refill reliability matter
Pediatric use	Material	Liquid, dispersible, and low-dose formats are valuable
Clinical differentiation	Limited for same active ingredient	Formulation and service differentiation are central
Generic risk	Real	Simple tablets and capsules are vulnerable
Biosimilar risk	None	No biologic interchangeability issue
Manufacturing complexity	Moderate to high for liquids	Pediatric products may have stronger barriers
Geographic opportunity	Global rare-disease markets	Registration and distribution capability are decisive

What revenue exposure and launch scenarios exist?

Product-level revenue for Orfadin and Nityr is not consistently disclosed in public financial reporting. The market should therefore be evaluated through patient count, treatment duration, dose distribution, net price, and geographic access rather than reported brand revenue alone.

Scenario 1: Low-cost generic tablet

This is the most direct competitive threat. It could reduce prices for patients able to use tablets, particularly adolescents and adults. The risk to liquid products would be lower if the generic does not offer an equivalent pediatric administration option.

Scenario 2: Pediatric dispersible product

A dispersible or mini-tablet product could command a premium if it improves administration and dose flexibility. Its success would depend on palatability, stability, caregiver usability, and reimbursement.

Scenario 3: Ready-to-use liquid

A ready-to-use liquid could compete with Orfadin suspension through convenience. The major commercial risks would be shipping cost, shelf life, preservative requirements, and payer resistance to a higher-cost product.

Scenario 4: Emerging-market access product

A heat-stable tablet or dry suspension with simplified packaging could expand access in markets where cold-chain or specialty-pharmacy distribution is limited. Regulatory registration and local pharmacovigilance would be more important than premium formulation economics.

Key Takeaways

• Nitisinone is a chronic orphan small-molecule therapy with established capsule, tablet, and suspension products.
• Orfadin and Nityr are the principal branded competitors.
• The strongest commercial opportunity is pediatric usability, not a new mechanism of action.
• A dispersible tablet, mini-tablet, or ready-to-use liquid could address gaps between capsules, tablets, and reconstituted suspension.
• Low-dose content uniformity is a central technical and regulatory challenge.
• Formulation patents should claim measurable technical improvements rather than conventional excipient combinations.
• Generic competition is plausible for tablets and capsules; pediatric suspensions present higher development and manufacturing barriers.
• Nitisinone has no biosimilar risk because it is a chemically synthesized small molecule.
• Excipient sourcing, global stability, microbial control, and dosing-device compatibility can create commercial differentiation.
• Product-level revenue is not consistently disclosed, so market sizing should rely on patient volume, treatment duration, dosage mix, and net pricing.

FAQs

Can nitisinone be formulated as a lactose-free product?

Yes. A lactose-free tablet, capsule, dispersible tablet, or liquid is technically feasible. Such a product could broaden use among patients and markets that avoid lactose-containing excipients.

Is a nitisinone oral suspension more difficult to manufacture than a tablet?

Yes. The suspension requires additional controls for particle size, sedimentation, redispersion, microbial quality, preservative effectiveness, and dose measurement.

What is the most defensible nitisinone formulation patent strategy?

The strongest strategy is usually a claim set tied to a measurable technical result, such as improved stability, dose uniformity, dispersibility, palatability, or suspension performance.

Could a nitisinone mini-tablet replace pediatric liquid products?

It could serve some children, but it would not eliminate the need for a liquid option. Age, swallowing ability, dose flexibility, and caregiver preference would determine substitution.

Does nitisinone require a biosimilar development strategy?

No. Nitisinone is a small molecule. Competitive development would use generic, hybrid, or standalone formulation pathways rather than biosimilar approval.

References

1. Swedish Orphan Biovitrum AB. (2024). Orfadin (nitisinone) capsules and oral suspension: U.S. prescribing information. U.S. Food and Drug Administration.

2. Cycle Pharmaceuticals Ltd. (2024). Nityr (nitisinone) tablets: U.S. prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (2002). Drugs@FDA: Orfadin application and approval history. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2017). Drugs@FDA: Nityr application and approval history. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugsatfda

6. U.S. Food and Drug Administration. (2024). Regulatory framework for generic drug products and abbreviated new drug applications. https://www.fda.gov/drugs/guidance-compliance-regulatory-information-guidances-drugs